Male Hypogonadism - Pipeline Review, H2 2017

  • ID: 4333982
  • Report
  • 100 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Antares Pharma Inc
  • EndoCeutics Inc
  • M et P Pharma AG
  • Merck & Co Inc
  • Repros Therapeutics Inc
  • The Female Health Company
  • MORE
Male Hypogonadism - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H2 2017, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 1, 4, 4, 2, 1 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Antares Pharma Inc
  • EndoCeutics Inc
  • M et P Pharma AG
  • Merck & Co Inc
  • Repros Therapeutics Inc
  • The Female Health Company
  • MORE
Introduction

Male Hypogonadism - Overview

Male Hypogonadism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism - Companies Involved in Therapeutics Development

Antares Pharma Inc

Clarus Therapeutics Inc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

TesoRx Pharma LLC

The Female Health Company

Viramal Ltd

Male Hypogonadism - Drug Profiles

BGS-649 - Drug Profile

corifollitropin alfa - Drug Profile

enclomiphene citrate - Drug Profile

IAS-167A - Drug Profile

Kisspeptin-10 - Drug Profile

leuprolide acetate - Drug Profile

Libidua - Drug Profile

LPCN-1111 - Drug Profile

MSS-722 - Drug Profile

testosterone - Drug Profile

testosterone - Drug Profile

testosterone - Drug Profile

testosterone - Drug Profile

testosterone enanthate - Drug Profile

testosterone propionate - Drug Profile

testosterone undecanoate - Drug Profile

testosterone undecanoate - Drug Profile

testosterone undecanoate - Drug Profile

testosterone undecanoate - Drug Profile

testosterone undecanoate - Drug Profile

testosterone undecanoate - Drug Profile

testosterone undecanoate - Drug Profile

Male Hypogonadism - Dormant Projects

Male Hypogonadism - Discontinued Products

Male Hypogonadism - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Male Hypogonadism, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Male Hypogonadism - Pipeline by Antares Pharma Inc, H2

Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2

Male Hypogonadism - Pipeline by EndoCeutics Inc, H2

Male Hypogonadism - Pipeline by Ferring International Center SA, H2

Male Hypogonadism - Pipeline by Lipocine Inc, H2

Male Hypogonadism - Pipeline by M et P Pharma AG, H2

Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2

Male Hypogonadism - Pipeline by Merck & Co Inc, H2

Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2

Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2

Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2

Male Hypogonadism - Pipeline by The Female Health Company, H2

Male Hypogonadism - Pipeline by Viramal Ltd, H2

Male Hypogonadism - Dormant Projects, H2

Male Hypogonadism - Discontinued Products, H2

List of Figures

Number of Products under Development for Male Hypogonadism, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Antares Pharma Inc
  • Clarus Therapeutics Inc
  • EndoCeutics Inc
  • Ferring International Center SA
  • Lipocine Inc
  • M et P Pharma AG
  • Medlab Clinical Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • Repros Therapeutics Inc
  • TesoRx Pharma LLC
  • The Female Health Company
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll